An Innovative Master Platform for Clinical Trials in Mood Disorders - Trial NCT06408012
Access comprehensive clinical trial information for NCT06408012 through Pure Global AI's free database. This phase not specified trial is sponsored by St. Joseph's Healthcare Hamilton and is currently Recruiting. The study focuses on Mood Disorders,Depressive Disorder,Bipolar and Related Disorders. Target enrollment is 900 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
St. Joseph's Healthcare Hamilton
Timeline & Enrollment
N/A
Oct 17, 2023
Mar 31, 2026
Primary Outcome
Rate of participation in the master trial platform
Summary
Mood disorders such as depression and bipolar disorder affect over 350 million people around
 the world. While several effective treatments exist, it is often difficult to match the right
 treatment to an individual person. Repeated efforts to find the right treatment contribute to
 poor functioning, low quality of life, and prolongs the time it takes to get well. Most areas
 of medicine are able to use 'biomarkers' or clinical tests, blood tests, or imaging to help
 diagnose and treat illness. The search for biomarkers in mood disorders is advancing, but one
 roadblock to progress is the lack of large, standardized studies of mood disorders that are
 needed to accurately identify biomarkers. The aim of the ENABLE platform is to provide the
 Canadian neuroscience community a standardized way of collecting biomarker data from
 individuals with a range of mood disorders symptoms. In addition, this 'master clinical trial
 platform' framework will provide a pool of participants who can be recruited into
 biomarker-based clinical trials.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06408012
Non-Device Trial